Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $14.00

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has received a consensus recommendation of “Buy” from the seven analysts that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $14.00.

A number of equities research analysts recently commented on BCRX shares. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, May 7th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, Director Steven K. Galson bought 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The stock was acquired at an average cost of $5.49 per share, with a total value of $120,450.60. Following the purchase, the director now directly owns 51,551 shares in the company, valued at approximately $283,014.99. The acquisition was disclosed in a filing with the SEC, which is available at this link. In other news, Director Nancy J. Hutson purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average cost of $6.38 per share, for a total transaction of $31,900.00. Following the completion of the transaction, the director now owns 86,818 shares of the company’s stock, valued at $553,898.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven K. Galson purchased 21,940 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The shares were purchased at an average price of $5.49 per share, with a total value of $120,450.60. Following the completion of the transaction, the director now directly owns 51,551 shares of the company’s stock, valued at approximately $283,014.99. The disclosure for this purchase can be found here. Insiders acquired a total of 93,240 shares of company stock valued at $530,342 in the last three months. 4.40% of the stock is currently owned by company insiders.

Institutional Trading of BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp grew its holdings in BioCryst Pharmaceuticals by 17,500.0% in the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,500 shares in the last quarter. Quarry LP acquired a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $54,000. Seven Eight Capital LP acquired a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at $57,000. Natixis lifted its stake in shares of BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 9,350 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 5,912 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Down 3.2 %

BioCryst Pharmaceuticals stock opened at $6.13 on Friday. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.96. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -5.73 and a beta of 1.96. The stock has a 50-day moving average price of $5.07 and a 200 day moving average price of $5.49.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million for the quarter, compared to analyst estimates of $85.62 million. During the same period last year, the firm earned ($0.28) EPS. The company’s revenue for the quarter was up 34.9% compared to the same quarter last year. Research analysts anticipate that BioCryst Pharmaceuticals will post -0.66 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.